2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-181835
    AgrC-IN-1 1448066-54-3
    AgrC-IN-1 is an AgrC inhibitor with an IC50 of 3.5 μM against Staphylococcus aureus AgrC. AgrC-IN-1 competitively binds to AgrC, inhibiting its autophosphorylation activity in Staphylococcus aureus. AgrC-IN-1 inhibits quorum sensing in Staphylococcus aureus, blocking virulence factor production. AgrC-IN-1 can be used for the research of Staphylococcus aureus infections.
    AgrC-IN-1
  • HY-181841
    TLR8 agonist 10 2796210-93-8
    TLR8 agonist 10 is a selective TLR8 agonist with an EC50 of 0.019 μM in humans. TLR8 agonist 10 activates TLR8-mediated signaling pathways. As a latency-reversing agent, TLR8 agonist 10 reactivates latent HIV-1 reservoirs. TLR8 agonist 10 activates innate cytotoxic natural killer cells to target HIV-infected CD4+ T cells. TLR8 agonist 10 is applicable to research related to HIV-1 infection.
    TLR8 agonist 10
  • HY-181864
    Rac1-IN-6 2310304-72-2
    Rac1-IN-6 (Compound 5e) is a selective Rac1 inhibitor and antimalarial agent. Rac1-IN-6 inhibits Rac1 activation induced by the Escherichia coli CNF1 toxin. Rac1-IN-6 suppresses the growth of chloroquine-sensitive Plasmodium falciparum D10 (IC50 = 76.0 nM) and chloroquine-resistant Plasmodium falciparum W2 (IC50 = 236.6 nM).
    Rac1-IN-6
  • HY-181866
    Antibacterial agent 328 2670430-25-6 98%
    Antibacterial agent 328 is a enoyl-ACP reductase (InhA) inhibitor and antimycobacterial agent. Antibacterial agent 328 blocks mycolic acid biosynthesis in Mycobacterium tuberculosis. Antibacterial agent 328 acts on both drug-resistant and drug-susceptible Mycobacterium tuberculosis strains. Antibacterial agent 328 exhibits favorable pharmacokinetic properties, drug-likeness, and a safety-related selectivity index. Antibacterial agent 328 can be used for research on tuberculosis.
    Antibacterial agent 328
  • HY-181870
    PROTAC SARS-CoV-2 Mpro degrader-8 98%
    PROTAC SARS-CoV-2 Mpro degrader-8 is an antiviral PROTAC degrader targeting the SARS-CoV-2 main protease (Mpro), with weak direct binding affinity to Mpro (Kd=80.5 μM). PROTAC SARS-CoV-2 Mpro degrader-8 exhibits broad-spectrum antiviral activity against SARS-CoV-2 and the human endemic coronavirus HCoV-OC43. It can be used for research on coronavirus infections.
    PROTAC SARS-CoV-2 Mpro degrader-8
  • HY-181888
    GRL-142 98%
    GRL-142 is a potent HIV-1 protease inhibitor capable of crossing the blood-brain barrier. GRL-142 exhibits extremely high inhibitory activity against both wild-type and multidrug-resistant strains (IC50=0.0094 nM). GRL-142 acts synergistically with the P2/P2' segments via a unique scaffold binding mechanism, utilizes fluorine-mediated stable interactions to maintain its bioactive conformation, adapts to p51 HIV-1 protease mutants, and maintains the flap-closed state by directly acting on the flap tip residues. GRL-142 disrupts the flap-water hydrogen bond network of wild-type protease, thereby effectively blocking viral replication. GRL-142 can be used to study HIV-1 infection and the associated neurocognitive disorder (HAND).
    GRL-142
  • HY-181892
    LpxC-IN-17
    LpxC-IN-17 (Compound a5) is a non-covalent LpxC inhibitor and Antibacterial agent. LpxC-IN-17 chelates catalytic zinc ions and forms extensive non-covalent interactions within the LpxC active site, thereby functionally inhibiting the enzyme. LpxC-IN-17 exhibits antibacterial activity against Gram-negative pathogens including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. LpxC-IN-17 is applicable to research related to Gram-negative bacterial infections.
    LpxC-IN-17
  • HY-181915
    PB2-IN-3
    PB2-IN-3 (Compound 11) is a PB2 inhibitor. PB2-IN-3 exhibits antiviral activity against Influenza A H1N1 and H3N2 strains. PB2-IN-3 can be used in studies related to influenza A virus infection.
    PB2-IN-3
  • HY-181920
    RPG-01-132 98%
    RPG-01-132 is a DENV capsid protein PROTAC degrader, with a DC50 of 2.4 μM. RPG-01-132 blocks viral assembly, eliminates viral particles, and interferes with the non-structural functions of capsid protein. RPG-01-132 exhibits significant antiviral activity against all four DENV serotypes and the ST148 (HY-121663)-resistant DENV2 mutant strain. RPG-01-132 is applicable to research related to dengue virus infection.
    RPG-01-132
  • HY-181927
    SARS-CoV-2 PLpro-IN-7
    SARS-CoV-2 PLpro-IN-7 (Compound 18) is a selective SARS-CoV-2 PLpro inhibitor with an IC50 of 13.3 μM. SARS-CoV-2 PLpro-IN-7 exerts antiviral activity against SARS-CoV-2 (with an EC50 of 11 μM for SARS-CoV-2 in Huh7.5 cells). SARS-CoV-2 PLpro-IN-7 is applicable to research related to COVID-19.
    SARS-CoV-2 PLpro-IN-7
  • HY-181933
    Clathrin-IN-5 339025-18-2 98%
    Clathrin-IN-5 (Compound 9) is a Clathrin N-terminal domain-Amphiphysin protein-protein interaction inhibitor with an IC50 of 2.77 μM. Clathrin-IN-5 inhibits the protein-protein interaction between the clathrin N-terminal domain and amphiphysin. Clathrin-IN-5 inhibits clathrin-mediated endocytosis with an IC50 of 4.6 μM. Clathrin-IN-5 inhibits the GTPase activity of Dynamin I with an IC50 of 29.7 μM.
    Clathrin-IN-5
  • HY-181935
    Antibiotic adjuvant 4 2493985-50-3 98%
    Antibiotic adjuvant 4 (Compound 13) is an Antibiotic adjuvant and efflux pump inhibitor. Antibiotic adjuvant 4 exhibits potent efflux pump inhibitory activity. Antibiotic adjuvant 4 significantly downregulates virulence-related genes of Staphylococcus aureus when used alone or in combination with antibiotics. Antibiotic adjuvant 4 enhances the efficacy of Ciprofloxacin (HY-B0356) against multiagent-resistant Staphylococcus aureus strains.
    Antibiotic adjuvant 4
  • HY-181939
    Antibacterial agent 329
    Antibacterial agent 329 (Compound 9c) is an antibacterial agent. Antibacterial agent 329 inhibits the activity of MraY. Antibacterial agent 329 exhibits antibacterial activity against Escherichia coli K12 and Bacillus subtilis W23 with a MIC of 16 μg/mL, but shows no activity against Pseudomonas fluorescens Pf-5. Antibacterial agent 329 exerts antibacterial activity against Acinetobacter baumannii 19606, Staphylococcus aureus MRSA USA300 JE2, Enterobacter cloacae 19434, Klebsiella pneumoniae 700603 and Enterococcus faecium 19434, with MIC values of 8, 8, 16-32, 16-32 and 16 μg/mL, respectively, while it shows no activity against Pseudomonas aeruginosa NCTC 13437.
    Antibacterial agent 329
  • HY-181985
    Insecticidal agent 30 69560-70-9
    Insecticidal agent 30 is an orally active insecticidal agent. Insecticidal agent 30 induces rapid contact mortality in adult Brassicogethes aeneus, achieves 100% 24-hour contact mortality against Brassicogethes aeneus, and exhibits moderate insecticidal activity against Drosophila melanogaster. Insecticidal agent 30 can be used for the research of pollen beetle (brassicogethes aeneus) infestation.
    Insecticidal agent 30
  • HY-181987
    PSCdb01560 98%
    PSCdb01560 is a Dengue virus NS5 RNA-dependent RNA polymerase (RdRp) inhibitor. PSCdb01560 binds stably to the conserved allosteric N-pocket of the polymerase, maintains persistent interactions with key residues Arg729 and Arg737, and induces polymerase structure stabilization. PSCdb01560 can be used for the research of dengue virus infection.
    PSCdb01560
  • HY-181991
    IRBM-Z-2 3014840-61-7
    IRBM-Z-2 is a non-competitive, orally active Zika virus (ZIKV) NS2B-NS3 protease inhibitor, with IC50 values of 0.04 μM and 3.1 μM against the wild-type and I156T mutant strains, respectively. IRBM-Z-2 exhibits broad-spectrum anti-flavivirus potential, with IC50 values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-1 inhibits ZIKV replication and alleviates virus-induced cytopathic effects. IRBM-Z-1 can be used in studies related to ZIKV infection.
    IRBM-Z-2
  • HY-182030
    RSV fusion protein IN-1
    RSV fusion protein IN-1 is an orally active RSV pre-fusion F protein inhibitor with an IC50 of 0.10 nM against RSV. RSV fusion protein IN-1 forms stable hydrogen bonds and π-π stacking interactions with pre-fusion F protein to block viral fusion and entry. RSV fusion protein IN-1 suppresses RSV F protein expression in epithelial cells. RSV fusion protein IN-1 reduces viral burden in the lungs of RSV-infected murine models.RSV fusion protein IN-1 can be used for the research of respiratory syncytial virus (RSV) infection.
    RSV fusion protein IN-1
  • HY-182042
    DENV-IN-15
    DENV-IN-15 is a sulfonyl anthranilic acid derivative and a pan-serotype anti-dengue virus (DENV) inhibitor with broad-spectrum anti-RNA virus activity. The EC50 value of DENV-IN-15 against DENV-2 in Huh-7 cells is 0.7 μM. DENV-IN-15 selectively regulates the translation of mRNAs encoding translation-related proteins and containing a 5'-oligopyrimidine tract. DENV-IN-15 reduces the expression of specific ribosomal proteins, thereby inhibiting viral replication. DENV-IN-15 exhibits enhanced membrane permeability, human plasma stability and human liver microsomal metabolic stability. DENV-IN-15 is applicable to research related to dengue virus infection.
    DENV-IN-15
  • HY-182276
    Anticandidal agent-2
    Anticandidal agent-2 is an anti-Candida albicans agent with a MIC of 1.6 μg/mL. Anticandidal agent-2 disrupts Candida albicans biofilms and inhibits Candida albicans. Anticandidal agent-2 can be used in the research of Candida albicans infections.
    Anticandidal agent-2
  • HY-182292
    SARS-CoV-2 3CLpro-IN-37 2920185-30-2
    SARS-CoV-2 3CLpro-IN-37 is a non-covalent SARS-CoV-2 3CLpro inhibitor with an IC50 of 3.2 nM. SARS-CoV-2 3CLpro-IN-37 blocks the cleavage and replication of viral polyproteins. SARS-CoV-2 3CLpro-IN-37 is applicable to research related to COVID-19.
    SARS-CoV-2 3CLpro-IN-37
Cat. No. Product Name / Synonyms Application Reactivity